A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
← catalyst calendarNCT07297212 · readout ≤ 529 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Bristol-Myers Squibb, BioNTech (Shanghai) Pharmaceuticals Co., Ltd..
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
75estimated
Sites
6
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-15 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Recurrent Glioblastoma
Interventions
- Drug: Pumitamig — also filed as PM8002, BNT327, BMS-986545
- Drug: Bevacizumab
- Drug: Temozolomide
Primary outcomes
what the primary-completion date above is the date OFConfirmed overall response rate (ORR)
measured Up to 24 months
Occurrence of treatment emergent adverse events (TEAEs) by severity
measured From the first dose of study treatment until 90 days after the last dose of study treatment (up to 27 months)
Occurrence of dose interruptions, reductions or discontinuations of study treatment due to TEAEs
measured Up to 24 months
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed